CoreAge Rx vs Vaylen
Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Vaylen head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 87 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
That doesn't make Vaylen a bad call — it's best for readers who want brand, compounded and oral options from one accredited nationwide desk without a premium sticker. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Vaylen | |
|---|---|---|
| Brief Score | 94/100 (A) | 87/100 (B+) |
| Semaglutide | $149/mo | $179/mo |
| Tirzepatide | $349/mo | $239/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.
Vaylen: $179 sema / $239 tirz; brand + oral + LegitScript across all 50 states.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.